Abstract： Objective： To observe the clinical effect of Ganfule Capsules combined with Huai'er Granules as adjuvant therapy after transcatheter arterial chemoembolization （TACE） for primary liver cancer. Methods： A retrospective analysis was conducted on 112 patients with primary liver cancer treated at the Affiliated Hospital of Shaoxing University from January 2020 to February 2023. The patients were divided into the control group and the observation group， with 56 patients in each， based on their treatment methods. Both groups received TACE for treatment. The control group was additionally treated with Lenvatinib Mesilate Capsules， while the observation group received Ganfule Capsules combined with Huai'er Granules on the basis of the control group's treatment. The clinical effects， 12-month survival rate， and incidence of adverse reactions were compared between the two groups. Additionally， the scores of traditional Chinese medicine （TCM） syndromes and the levels of blood platelet count （BPC）， albumin （Alb）， alpha-fetoprotein （AFP）， protein induced by vitamin K absence or antagonist- Ⅱ（PIVKA-Ⅱ）， total bilirubin （TBil）， aspartate aminotransferase （AST）， and alanine aminotransferase （ALT） were compared before and after treatment. Results：After treatment，there was no statistically significant difference in disease control rate between the two groups （P＞0.05）. The objective response rate， 12-month survival rate， and incidence of adverse reactions in the observation group were 41.07%（ 23/56），98.21%（ 55/56），and 35.71%（ 20/56）， respectively， compared with 23.21% （13/56）， 83.93% （47/56）， and 55.36% （31/56） in the control group， differences between the two groups being significant （P＜0.05）. After treatment，the BPC and Alb levels in both groups were increased when compared with those before treatment （P＜0.05），while the TCM syndrome scores and the levels of AFP，PIVKA-Ⅱ，TBil，AST，and ALT were all reduced （P＜0.05）. The BPC and Alb levels in the observation group were higher than those in the control group after treatment （P＜0.05），while the TCM syndrome scores and the levels of AFP，PIVKA-Ⅱ，TBil，AST，and ALT were lower than those in the control group（ P＜0.05）. Conclusion： Ganfule Capsules combined with Huai'er Granules as adjuvant therapy after TACE for primary liver cancer has a definite effect，can improve liver function，reduce tumor marker levels，and has a high safety profile.